Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria). RESULTS: EQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m2 [95% CI −0.27 to 0.70]). Macroalbuminuria occurred in 2.2% of patients in the EQW group and in 2.5% of those in the placebo group (hazard ratio [HR] 0.87 [95% CI 0.70–1.07]). Neither renal composite was reduced with EQW in unadjusted analyses, but renal composite 2 was reduced after adjustment (HR 0.85 [95% CI 0.74–0.98]). Retinopathy rates did not differ by treatment group or in the HbA1c-lowering or prior retinopathy subgroups. CV outcomes in those with eGFR <60 mL/min/1.73 m2 did not differ by group. Those with eGFR ≥60 mL/min/1.73 m2 had nominal risk reductions for MACE, all-cause mortality, and CV death, but interactions by renal function group were significant for only stroke (HR 0.74 [95% CI 0.58–0.93]; P for interaction = 0.035) and CV death (HR 1.08 [95% CI 0.85–1.38]; P for interaction = 0.031). CONCLUSIONS: EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“subsequent analysis of the data adjusted for baseline demographics and comorbidities revealed a significant improvement in the renal composite outcome, mainly mediated by a lower incidence of macroalbuminuria [58].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Cited by
Items 101–117 of 117
GLP-1-receptoragonisták szerepe a krónikus vesebetegségben
Sztanek, F., Tóth, L., & Hernyák, M. (2024) · Diabetologia Hungarica · doi:10.24121/dh.2024.3
In Reply: Diabetic retinopathy: Screening, prevention, and treatment
Chong, D. D., Das, N., & Singh, R. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91c.12002
López, J. P., Capote, P. A. C., Pozo, A. H., Guerra, L. C., García, J. L., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501359 · Cited by 1
Perencin, A., Ceolin, C., Papa, M. V., Marzio, B. D., Zanforlini, B. M., Devita, M., Curreri, C., GASPARINI, G., Sergi, G., & RUI, M. D. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09709-5
Arif, A., Lama, S., Singla, B., Singla, S., Kumawat, S., Tharwani, A., Usman, M., Khalid, H., Kanukollu, V. M. R., Ekomwereren, O., et al. (2025) · Cureus · doi:10.7759/cureus.92976
“The SUSTAIN-6 trial (Marso et al. [11]) uniquely identified a significant increase in DR complications with semaglutide, in contrast to EXSCEL (Bethel et al., [12]) and REWIND (Kwan et al., [13]), which showed neutral effects on retinopathy outcomes.”
InfluentialLópez, J. P., Capote, P. A. C., Pozo, A. H., Castilla‐Guerra, L., Fernández‐García, J. C., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501359 · Cited by 1
“Fuente: tabla realizada con datos de Muskiet et al. 58 , Marso et al. 59,60 , Bethel et al. 61 , Hernandez et al. 62 , Gerstein et al. 63 , Husain et al. 64 y Perkovic et al. 65 . placebo.”
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612690
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612693
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612687
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612684
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612675
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612681
Rossing, P., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. G. (2023) · Figshare · doi:10.6084/m9.figshare.26612678
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Chen, H., Wu, X., Yuan, M., Ren, F., Liu, T., Yang, L., An, X., & Zhan, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1937754
Eskandar, K., Attiya, K. I., Abdou, H. A., & Seffen, P. M. (2026) · World Journal of Nephrology · doi:10.5527/wjn.126698
Metadata
- Authors
- Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C., Goodman, S. G., Iqbal, N., Jakuboniene, N., Katona, B., Lokhnygina, Y., Lopes, R. D., Maggioni, A. P., Ohman, P., Tankova, T., Bakris, G. L., Hernandez, A. F., & Holman, R. R.
- Affiliations
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Duke University (US)
- University of North Carolina at Chapel Hill (US)
- Chinese University of Hong Kong (HK)
- St. Michael's Hospital (CA)
- AstraZeneca (United States) (US)
- Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- AstraZeneca Research and Development, Gaithersburg, MD
- Medical University of Sofia (BG)
- University of Chicago (US)
- Corresponding author
- Holman, Rury R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-11-22
- Volume
- 43
- Issue
- 2
- Pages
- 446-452
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7411285
- OpenAlex
- W2989595227
- Cited by
- 112
- References
- 32
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 9 · 2023: 22 · 2022: 22 · 2021: 13 · 2020: 17
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0515-10096)
- National Institutes of Health (UL1TR002489)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- exenatide, GLP-1 receptor agonists, renal function, estimated glomerular filtration rate, macroalbuminuria, diabetic retinopathy, major adverse cardiovascular events, cardiovascular risk reduction, renal function decline, stroke, renal replacement therapy, renal death, type 2 diabetes, EXSCEL trial, subgroup analysis, drug safety in renal impairment, all-cause mortality
- MeSH terms
- Exenatide, Aged, Cardiovascular Diseases, Cardiovascular System, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Middle Aged, Risk Factors, Survival Analysis, Treatment Outcome, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.